A Comparison of Blood and Tissue Biomarkers Before and After Nephrectomy in the First-line Setting With Everolimus in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Trial Profile

A Comparison of Blood and Tissue Biomarkers Before and After Nephrectomy in the First-line Setting With Everolimus in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Acronyms NEORAD
  • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results of an exloratory analysis (n=25) presented at the 42nd European Society for Medical Oncology Congress.
    • 18 Aug 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top